The SEC has settled insider-trading charges against Weizheng Zeng in an administrative proceeding arising from the acquisition of Chimerix, Inc. by Jazz Pharmaceuticals plc. In SEC v. Weizheng Zeng (File No. 3-22627), the agency alleged that Zeng traded Chimerix stock while participating in due diligence work connected to Jazz’s acquisition of the company, before the deal was publicly announced on March 5, 2025.

According to the SEC, those trades generated roughly $69,011 in illicit profits. Without admitting or denying the findings, Zeng agreed to a cease-and-desist order and monetary relief including disgorgement, prejudgment interest, and a civil penalty equal to the alleged profits. The matter was brought as an administrative proceeding rather than a federal district court action, but it carries the same core message the SEC has been emphasizing for years: access to deal information through professional roles can create immediate and serious insider-trading exposure.

For legal and compliance teams, the case is a useful reminder that insider-trading risk in M&A is not limited to executives, bankers, or board members. Anyone pulled into a transaction process—including consultants, diligence personnel, technical specialists, and other outside participants—may become a temporary insider once they receive material nonpublic information. That is especially relevant in life sciences deals, where small-cap public company targets can experience sharp stock movement on acquisition news.

The matter also underscores the compliance challenge around “need-to-know” access. In-house counsel overseeing strategic transactions should review who is brought into diligence, how confidentiality obligations are documented, whether restricted-list procedures are updated in real time, and whether trading blackout reminders extend beyond the core deal team. For litigators and enforcement lawyers, the case shows how the SEC continues to pursue relatively modest-profit trades where the facts fit a classic misappropriation or confidentiality-based theory.

The underlying transaction context—Jazz Pharmaceuticals’ acquisition of Chimerix—illustrates why deal diligence remains a recurring enforcement flashpoint. Once an acquisition process advances, information about valuation, timing, and strategic intent can quickly become market-moving. Even a single round of trading before announcement can produce a straightforward evidentiary narrative for the government, particularly where access logs, confidentiality agreements, and trading records line up.

For practitioners tracking SEC enforcement trends, this settlement is another example of the agency’s continued focus on policing trading around corporate events and on holding individuals accountable when they allegedly misuse information obtained through transactional work. Compliance officers and deal counsel may want to treat it as a prompt to revisit insider-trading controls before the next confidential M&A process begins.